0
Signin
countryflagUS

18889881171

AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%

Pacira Pharmaceuticals Inc

Healthcare US PCRX

25.5USD
-0.4(1.54%)

Last update at 2024-04-25T20:00:00Z

Day Range

25.3326.00
LowHigh

52 Week Range

25.9348.60
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 13.30M 56.40M 20.09M -10.74800M -0.42500M
Minority interest - - - - -
Net income 15.91M 41.98M 145.52M -11.01600M -0.47100M
Selling general administrative 109.52M 88.32M 74.83M 71.12M 70.16M
Selling and marketing expenses 145.00M 111.02M 118.68M 129.66M 107.11M
Gross profit 467.53M 401.28M 303.50M 314.31M 250.43M
Reconciled depreciation 91.50M 13.55M 19.91M 19.58M 13.16M
Ebit 60.02M 131.06M 46.35M 38.11M 9.92M
Ebitda 121.47M 144.62M 66.86M 43.81M 23.09M
Depreciation and amortization 61.45M 13.55M 20.51M 5.70M 13.16M
Non operating income net other - -1.77000M -0.59000M 2.40M 5.61M
Operating income 60.02M 131.06M 46.35M 38.11M 15.91M
Other operating expenses 595.90M 408.70M 378.13M 385.32M 319.80M
Interest expense 39.98M 31.75M 25.67M 23.63M 21.95M
Tax provision -2.60700M 14.42M -125.43400M 0.27M 0.05M
Interest income 4.54M 0.90M 4.63M 7.38M 6.50M
Net interest income -35.43400M -30.85400M -21.04200M -16.25200M -15.45200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.60700M 14.42M -125.43400M 0.27M 0.05M
Total revenue 666.82M 541.53M 420.83M 421.03M 337.28M
Total operating expenses 396.60M 268.44M 260.80M 278.60M 232.95M
Cost of revenue 199.29M 140.25M 117.33M 106.71M 86.84M
Total other income expense net -46.72200M -74.66100M -26.26100M -48.85800M -2.45200M
Discontinued operations - - - - -
Net income from continuing ops 15.91M 41.98M 145.52M -11.01600M -0.47100M
Net income applicable to common shares 15.91M 41.98M 145.52M -11.01600M -0.47100M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 1681.20M 2075.35M 1274.51M 831.07M 689.35M
Intangible assets 540.55M 623.97M 96.52M 104.39M -
Earning assets - - - - -
Other current assets 15.22M 14.77M 12.27M 10.78M 7.95M
Total liab 906.19M 1344.94M 654.83M 476.12M 368.13M
Total stockholder equity 775.01M 730.41M 619.69M 354.94M 321.23M
Deferred long term liab - - - - -
Other current liab 89.78M 117.86M 14.74M 18.18M 45.95M
Common stock 0.05M 0.04M 0.04M 0.04M 0.04M
Capital stock 0.05M 0.04M 0.04M 0.04M 0.04M
Retained earnings -148.75100M -211.89500M -253.87500M -399.39800M -388.22600M
Other liab 37.79M 77.57M 17.44M 21.46M 16.87M
Good will 163.24M 145.18M 99.55M 99.55M 62.04M
Other assets 160.31M 153.36M 290.13M 0.97M 0.70M
Cash 104.14M 585.58M 99.96M 78.23M 132.53M
Cash and equivalents - - - - -
Total current liabilities 147.77M 521.12M 253.33M 107.67M 60.66M
Current deferred revenue - 10.12M 71.09M 71.76M -
Net debt 659.25M 543.27M 441.17M 273.69M 158.40M
Short term debt 42.77M 382.59M 157.07M 4.93M 0.34M
Short long term debt 33.65M 374.70M 149.65M - 0.34M
Short long term debt total 763.39M 1128.85M 541.13M 351.92M 290.93M
Other stockholder equity 924.10M 942.09M 873.20M 753.98M 709.69M
Property plant equipment 254.39M 264.81M 136.69M 104.68M 108.67M
Total current assets 498.33M 866.05M 651.62M 408.56M 477.97M
Long term investments 64.38M 21.99M 109.48M 64.80M 25.87M
Net tangible assets 71.22M -38.73500M 423.62M 151.01M 259.19M
Short term investments 184.51M 70.83M 421.70M 213.72M 250.93M
Net receivables 98.40M 96.32M 53.05M 47.53M 38.00M
Long term debt 655.82M 674.53M 313.03M 306.05M 290.59M
Inventory 96.06M 98.55M 64.65M 58.30M 48.57M
Accounts payable 15.22M 10.54M 10.43M 12.80M 14.37M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.38000M 0.17M 0.32M 0.32M -0.28000M
Additional paid in capital - - - - -
Common stock total equity - 0.04M 0.04M 0.04M 0.04M
Preferred stock total equity - - - - -
Retained earnings total equity - -211.89500M -253.87500M -399.39800M -388.22600M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 27.17M 76.41M 74.49M 10.97M 0.66M
Deferred long term asset charges - - - - -
Non current assets total 1182.87M 1209.31M 622.89M 422.51M 211.38M
Capital lease obligations 73.92M 79.62M 78.45M 45.87M -
Long term debt total - - 313.03M 306.05M 290.59M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -225.18500M 449.12M -239.80600M 0.98M 41.93M
Change to liabilities 6.27M -10.13700M -11.77800M 11.66M 5.53M
Total cashflows from investing activities -225.18500M -20.79000M -277.60700M -128.48800M 20.58M
Net borrowings -427.69400M 363.75M 125.43M -0.33800M -0.33800M
Total cash from financing activities -401.52800M 380.69M 222.30M 3.67M 8.95M
Change to operating activities -23.11200M -0.47100M -18.61400M 9.23M 2.87M
Net income 15.91M 41.98M 145.52M -11.01600M -0.47100M
Change in cash -481.43900M 485.62M 21.73M -54.29800M 78.40M
Begin period cash flow 585.58M 99.96M 78.23M 132.53M 54.13M
End period cash flow 104.14M 585.58M 99.96M 78.23M 132.53M
Total cash from operating activities 145.27M 125.72M 77.03M 70.52M 48.87M
Issuance of capital stock - - - - -
Depreciation 91.50M 28.55M 19.91M 19.58M 13.16M
Other cashflows from investing activities - -424.04200M - -119.31300M -6.84300M
Dividends paid - 2.67M 1.62M 4.32M -
Change to inventory 2.49M -4.46700M -6.35300M -8.02600M -7.15700M
Change to account receivables -2.07900M -10.43400M -5.51600M -8.52400M -5.99900M
Sale purchase of stock 2.95M 2.81M 45.22M 8.47M 7.17M
Other cashflows from financing activities -1.17500M 380.56M 433.80M 8.32M 8.95M
Change to netincome 57.59M 54.79M -75.01400M 55.65M 32.64M
Capital expenditures 30.08M 45.87M 37.80M 10.16M 14.51M
Change receivables - -10.43400M -5.51600M -8.52400M -5.99900M
Cash flows other operating - -5.69300M -10.14800M -4.25500M -3.22800M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 485.62M 21.73M -54.29800M 78.40M
Change in working capital -16.43300M -18.67400M -24.38600M -8.77000M -10.85700M
Stock based compensation 48.09M 42.25M 39.92M 33.65M 31.73M
Other non cash items 14.15M 20.75M 22.68M 31.75M 14.39M
Free cash flow 115.20M 79.85M 39.23M 60.36M 34.36M

Fundamentals

  • Previous Close 25.90
  • Market Cap1534.77M
  • Volume303886
  • P/E Ratio220.33
  • Dividend Yield-%
  • EBITDA155.09M
  • Revenue TTM665.69M
  • Revenue Per Share TTM14.45
  • Gross Profit TTM 393.23M
  • Diluted EPS TTM0.15

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PCRX
Pacira Pharmaceuticals Inc		 -0.4 1.54% 25.50 220.33 9.22 2.25 1.80 2.78 15.22
ZTS
Zoetis Inc		 2.48 1.64% 153.36 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.37 1.14% 32.07 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 6.97 4.40% 165.33 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.16 1.21% 13.07 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Pacira Pharmaceuticals Inc

5401 West Kennedy Boulevard, Tampa, FL, United States, 33609

Key Executives

Name Title Year Born
Mr. David M. Stack Chairman & CEO 1950
Mr. Charles A. Reinhart III, CPA, M.B.A. Chief Financial Officer 1961
Dr. Roy Winston M.D. Chief Medical Officer 1962
Mr. Max Reinhardt Pres of Rest of World 1971
Dr. Jonathan Slonin M.D. Chief Clinical Officer 1975
Mr. Daryl Gaugler Chief Operating Officer 1962
Ms. Lauren Bullaro Riker Principal Accounting Officer & VP of Fin. 1979
Mr. Charles Laranjeira Chief Technical Officer 1966
Ms. Kristen Williams J.D. Chief Admin. Officer & Sec. 1974
Susan Mesco Head of Investor Relations NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).